Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Spexis Logo
Spexis Growth Score
68
CB Rank
198837
Heat Score
51
Spexis is a swiss pharma company focusing on the discovery and development of macrocycle drugs addressing high unmet medical needs.
Founded
obfuscation
PublicPost-IPO Debt Allschwil, Basel-Landschaft, Switzerland11-50 spexisbio.com/
Biotechnology
Medical
Pharmaceutical
Overview

Spexis
Total Funding
obfuscation
Growth Score
68
Heat Score
51

Total Funding
obfuscation
obfuscation
Post-IPO Debt raised
obfuscation
Growth Score68
-13 pts
in past quarter
Heat Score 51
-6 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
See more interactive data and historical milestones on desktop for the best experience

About Spexis

CB Rank
198837
Spexis is a swiss pharma company focusing on the discovery and development of macrocycle drugs addressing high unmet medical needs.
Founded
obfuscation
PublicPost-IPO Debt Allschwil, Basel-Landschaft, Switzerland11-50 spexisbio.com/
Biotechnology
Medical
Pharmaceutical

Funding Rounds

Post-IPO Debt
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Debt Financing
OBF
in
obfuscation

Key People

Details

Legal Name Spexis AG
Also Known As Polyphor, Polyphor Ltd.
Operating Status Active
Stock Symbol  SIX:SPEX
Company Type For Profit
Founders  Daniel Obrecht, Jean-Pierre Obrecht
About the Company

Polyphor is a Swiss Pharma company focusing on the discovery and development of macrocycle drugs addressing high unmet medical needs.

Polyphor was founded in 1996 and is a clinical stage, privately held Swiss specialty pharma company, based in Allschwil near Basel. It focuses on the development of macrocycle drugs that address antibiotic

resistance and severe respiratory diseases.

Phone Number 41615671601
Contact Email info@polyphor.com
Predictions & Insights

Growth Insight

See this Growth Insight
Spexis is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

Inhaled Murepavadin
An inhaled antibiotic targeting Pseudomonas aeruginosa infections in cystic fibrosis and non-CF bronchiectasis patients.
Balixafortide
A macrocyclic CXCR4 inhibitor studied for oncology and rare disease indications, including solid tumors and hematologic malignancies.

Research & Development

Spexis is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 11
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - Spexis Logo
Post-IPO Debt - Spexis
1
obfuscation
SPRIM Global InvestmentsPost-IPO Debt
obfuscation
Post-IPO Debt - Spexis Logo
Post-IPO Debt - Spexis
1
obfuscation
SPRIM Global InvestmentsPost-IPO Debt
obfuscation
Post-IPO Debt - Spexis Logo
Post-IPO Debt - Spexis
1
obfuscation
SPRIM Global InvestmentsPost-IPO Debt
obfuscation
Post-IPO Debt - Spexis Logo
Post-IPO Debt - Spexis
1
obfuscation
SPRIM Global InvestmentsPost-IPO Debt
obfuscation
Post-IPO Debt - Spexis Logo
Post-IPO Debt - Spexis
1
obfuscation
SPRIM Global InvestmentsPost-IPO Debt

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 11
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - Spexis Logo
Post-IPO Debt - Spexis
1
obfuscation
SPRIM Global InvestmentsPost-IPO Debt
obfuscation
Post-IPO Debt - Spexis Logo
Post-IPO Debt - Spexis
1
obfuscation
SPRIM Global InvestmentsPost-IPO Debt
obfuscation
Post-IPO Debt - Spexis Logo
Post-IPO Debt - Spexis
1
obfuscation
SPRIM Global InvestmentsPost-IPO Debt
obfuscation
Post-IPO Debt - Spexis Logo
Post-IPO Debt - Spexis
1
obfuscation
SPRIM Global InvestmentsPost-IPO Debt
obfuscation
Post-IPO Debt - Spexis Logo
Post-IPO Debt - Spexis
1
obfuscation
SPRIM Global InvestmentsPost-IPO Debt

Investors

Investments

Number of Acquisitions 1

Investment Breakdown

Number of Acquisitions 1
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 3 Board Members and Advisors 2 Contacts 8

Employee Profiles

Board Members and Advisors

News

News and Press

News•Nov 25, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Nov 5, 2024
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jul 29, 2024
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jul 22, 2024
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

770
536.36%
 in past month

IT Spend

$291.3KThis year, Spexis is projected to spend $291.3K on IT, according to Aberdeen.

Actively Used Products

11Spexis uses 11 technology products and services including HTML5, Lightbox, and  Bootstrap, according to G2 Stack.

Active Website Tech Count

10Spexis is actively using 10 technologies for its website, according to BuiltWith. These include IPhone / Mobile Compatible, Euro, and  DoubleClick.Net.

Total IP

11The intellectual property of Spexis includes 11 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Spexis's headquarters? Spexis is located in Allschwil, Basel-Landschaft, Switzerland.Who invested in Spexis? Spexis has 6 investors including SPRIM Global Investments and  SPRIM Global Investments.When was the last funding round for Spexis? Spexis closed its last funding round on
obfuscation
from a Post-IPO Debt round.Who are Spexis's competitors? Alternatives and possible competitors to Spexis may include Tango Therapeutics, Onco-Innovations, and  C4 Therapeutics.How much funding has Spexis raised to date? Spexis has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(d29fb2e 1)
|